Onzima Ventures
PLC
("Onzima" or the "Company")
Investee company
N4 Pharma announces formation of scientific advisory panel
N4 Pharma Limited (“N4 Pharma”), in which Onzima holds a 49%
equity stake, has announced that its intellectual property partner
OPAL IP has formed a scientific
advisory panel to provide advice and guidance on N4 Pharma’s
reformulation projects, the first of which is its reformulation of
sildenafil.
The panel is made up of Professor Karrar
Khan, formerly Head of Pharmaceutical Development for Boots
Pharmaceuticals and Knoll, Doctor David
Templeton, an expert in pharmacokinetics and translational
science, and Doctor Sean McCrossen,
an expert in pharmaceutical development.
N4 Pharma CEO Nigel Theobald
commented:
“This is a very strong advisory panel which together brings over
90 years’ experience to our development programs. It will be a huge
asset to help make sure that our reformulations meet the
requirements of industry and the regulators and we are delighted
that OPAL IP has been able to put
together such a strong team.”
For further information please
contact:
Onzima Ventures PLC
Tel: +44 (0) 1732 366 561
Gavin Burnell, Luke Cairns
Nominated Adviser
Cairn Financial Advisers
LLP
Tel:
+44 (0) 20 7148 7900
Sandy Jamieson, Liam Murray
Broker
Peterhouse Corporate Finance
Limited
Tel: +44 (0) 20 7469 0930
Guy Miller, Lucy Williams